Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-11-06
2007-11-06
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S206000, C544S216000, C514S241000
Reexamination Certificate
active
10285364
ABSTRACT:
The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity and/or proliferation of cells such as tumor cells.
REFERENCES:
patent: 3119823 (1964-01-01), Shapiro et al.
patent: 3933814 (1976-01-01), Haberkorn et al.
patent: 3948893 (1976-04-01), Aichinger et al.
patent: 3966725 (1976-06-01), Reisdorff et al.
patent: 4219552 (1980-08-01), Haberkorn et al.
patent: 4499269 (1985-02-01), Bennion et al.
patent: 5102927 (1992-04-01), Rody et al.
patent: 5260362 (1993-11-01), Rody et al.
patent: 5545836 (1996-08-01), Reinehr et al.
patent: 5702717 (1997-12-01), Cha et al.
patent: 5856331 (1999-01-01), Bursten
patent: 5962453 (1999-10-01), Ueda et al.
patent: 6004985 (1999-12-01), Kochanny et al.
patent: 6150360 (2000-11-01), Daeyaert et al.
patent: 6150362 (2000-11-01), Henkin et al.
patent: 6150382 (2000-11-01), Kochanny et al.
patent: 6166014 (2000-12-01), Kochanny et al.
patent: 6193960 (2001-02-01), Metzger et al.
patent: 6288228 (2001-09-01), Henkin et al.
patent: 1200314 (1965-09-01), None
patent: 2226474 (1973-02-01), None
patent: 525 262 (1993-02-01), None
patent: 0525262 (1993-05-01), None
patent: 1321624 (1963-03-01), None
patent: 0963814 (1962-01-01), None
patent: 48-28486 (1973-04-01), None
patent: 49-69688 (1974-07-01), None
patent: 274102 (1970-04-01), None
patent: WO91/11465 (1991-08-01), None
patent: WO 00/25780 (2000-05-01), None
patent: WO-00/25780 (2000-05-01), None
patent: WO 01/25220 (2001-04-01), None
patent: WO 01/25220 (2001-04-01), None
patent: WO 02/36578 (2002-05-01), None
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition,vol. 1, 1004-1010, 1996.
Hasan et al. Expert Opin. Bio. Ther. 1(4): 703-718, 2001.
Pergram et al. Semin. Oncol. 3 Suppl 11: 29-37, 2002.
Koizumi et al., Nippon Noyaku Gakaishi 19(2), 85-92, 1994, CA 121: 157609, 1994.
Elkafrawy et al., Phosphorus, Sulfur and Silicon and the Related Elements 62(1-4),275-279, 1991, CA 115: 279963, 1991.
Moussa et al., Journal of Chemical Society of Pakistan 11(3), 194-199, 1989, CA 113: 59112, 1990.
Yuki et al., Kobunshi Ronbunshu 40(11), 739-744, 1984, CA 100: 103965, 1984.
Seo et al., Kobunshi Ronbunshu 31(6), 401-405, 1974, CA 81: 169925, 1974.
Murai et al., JP 49069688, CA 81: 136188, 1974.
Ohto et al., Bulletin of the Chemical Society of Japan 47(5), 1301-1302, 1974, CA 81: 37076, 1974.
Yuki et al., Nagoya Kogyo Daigaku Gakuho 24, 423-427, 1972, CA 81: 403898, 1974.
Yuki et al., Nippon Kagaku Kaishi 1, 103-107, 1974, CA 80: 82903, 1974.
Michalik et al., Wissenschaftliche Zeitschrift der Universitaet Rostock, Mathematisch Naturwissenschaftliche Reihe 21(2), 101-111, 1972, CA 79: 18680, 1973.
Masuda et al., JP 48028486, CA 78: 159683, 1973.
Yuki et al., Bulletin of the Chemical Society of Japan 44(9), 2444-2447, 1971, CA 75: 151765, 1971.
Yuki et al., Bulletin of the Chemical Society of Japan 43(7), 2130-2134, 1970, CA 73: 56484, 1970.
Fomenko et al., Vysokomolekulyarnye Soedineniya Seriya B: Kratkie Soobshcheniya 11 (5), 387-390, 1969, CA 71: 39618, 1969.
Burmistrov et al., SU 162150, CA 61: 47941, 1964.
Bonham et al., Expert Opin. Ther. Targets 7(5): 643-661, 2003.
Brodskii et al., “The mechanism underlying the action of secondary aromatic amine- type antioxidants and their ether on the radiation oxidation of N-butylpropionamide and polycaproamide,”Chemical Abstracts, Accession No. 69:3284, 1968.
Budesinsky et al., “Substituted 2,4-diamino-6-phenyl-1,3,5-triazines,”Chemical Abstracts, Accession No. 97:6328, 1982.
Burmistrov et al., “6-Amino-4-arylamino-2-(o-hydroxyphenyl) triazines,”Chemical Abstracts, Accession No. 61:47941, 1964.
Chen, C. et al., “A Convenient Synthetic Method for Trisubstituted s-Triazines,”Chemical Abstracts, Accession No. 124:146076, 1995.
Elkafrawy, A.F. et al., “Synthesis and reaction of some 4-aryl-2-benzylthio-1, 6-dihydro-6-thiono-1,3,5-triazines,”Chemical Abstracts, Accession No. 115:279963, 1991.
Michalik, M. et al., “Synthesis of nitrogen-containing heterocycles,”Chemical Abstracts, Accession No. 79:18680, 1973.
Moussa, G.E.M. et al., “Some reactions on 4-aryl-2-substituted amino-1,6-dihydro-6-thioxo-1,3,5 triazines,”Chemical Abstracts, Accession No. 113:59112, 1990.
Shapiro, S.L. et al., “Guanamines. VIII. 6-(Substituted-phenyl) guanamines,”Chemical Abstracts, Accession No. 56:60602, 1962.
Yuki, Y. et al., “Preparation of amino-s-triazines with amino or nitrophenyl groups,”Chemical Abstracts, Accession No. 75:151765, 1971.
Moolenaar, W.H., “Lysophosphatidic Acid, a Multifunctional Phospholipid Messenger,”Journal of Biological Chemistry 270(22): 12949-12952, Jun. 2, 1995.
Xu et al, “Lysophospholipids activate ovarian and breast cancer cells,”Biochemical Journal 309: 933-940, Aug. 1, 1995.
Imamura et al, “Induction of in vitro tumor cell invasion of cellular monolayers by lysophosphatidic acid or phospholipase D,”Biochemical and Biophysical Research Communications 193(2): 497-503, Jun. 15, 1993.
Bursten et al., “Lipid A activation of glomerular mesangial cells: mimicry of the bioactive lipid, phophatidic acid,”American Journal of Physiology 262(2): C328-C338, Feb. 1992.
Bursten et al., “Interleukin-1 Rapidly Stimulates Lysophosphatidate Acyltransferase and Phosphatidate Phosphohydrolase Activities in Human Mesangial Cells,”Journal of Biological Chemistry 266(31): 20732-20743, Nov. 5, 1991.
Kester, M., “Platelet-Activating Factor Stimulates Phosphatidic Acid Formation in Cultured Rat Mesangial Cells: Roles of Phospholipase D, Diglyceride Kinase, and De Novo Phospholipid Synthesis,”Journal of Cellular Physiology 156: 317-325, 1993.
English, D., “Phosphatidic acid: A lipid messenger involved in intracellular and extracellular signaling,”Cell Signal 8(5): 341-347, 1996.
Martin et al., “Increased concentrations of phosphatidate diacylglycerol and ceramide inras- and tyrosine kinase (fps)-transformed fibroblasts,”Oncogene 14(13):1571-1580, Apr. 3, 1997.
Rizzo et al., “The Recruitment of Raf-1 to Membranes Is Mediated by Direct Interaction with Phosphatidic Acid and Is Independent of Association with Ras,”Journal of Biological Chemistry 275(31): 23911-23918, Aug. 4, 2000.
Stamps et al., “A human cDNA sequence with homology to non-mammalian lysophosphatidic acid acyltransferases,”Biochemical Journal 326:455-461, Sep. 1, 1997.
Kume and Shimizu, “cDNA Cloning and Expression of Murine 1-Acyl-sn-glycerol-3-phosphate Acyltransferase,”Biochemical and Biophysical Research Communications 237(3): 663-666, Aug. 28, 1997.
West et al., “Cloning and Expression of Two Human Lysophosphatidic Acid Acyltransferase cDNAs That Enhance Cytokine-Induced Signaling Responses in Cells,”DNA and Cell Biology 16(6): 691-701, Jun. 1997.
Eberhardt et al., “Human Lysophosphatidic Acid Acyltransferase,”Journal of Biological Chemistry 272(32): 20299-20305, Aug. 8, 1997.
Leung et al., “Molecular Cloning of Two Alternatively Spliced Forms of Human Phosphatidic Acid Phosphatase cDNAs that Are Differentially Expressed in Normal and Tumor Cells,”DNA and Cell Biology 17(4): 377-385, Apr. 1998.
Fong and Engleman, “Dendritic Cells in Cancer Immunotherapy,”Annual Review of Immunology 18: 245-273, 2000.
Schreurs et al., “Dendritic Cell-Based Vaccines: From Mouse Models to Clinical Cancer Immunotherapy,”Critical Reviews in Oncogenesis 11(1): 1-17, 2000.
Miller and Rosman, “Improved Retroviral Vectors for Gene Transfer and Expression,”BioTechniques 7(9): 980-EOA, Oct. 1989.
Hoess and Abremski, “The Cre-loxRecombination System,”Nucleic Acids and Molecular Biology 4: 99-109, 1990.
Sauer, B., “Inducible Gene Targeting in Mice Using the Cre/loxSystem,”Methods: A Companion to Methods in Enzymology 14(4): 381-392, Apr. 1998.
Wetmur
Bhatt Rama
Gong Baoqing
Hong Feng
Jenkins Scott A.
Klein J. Peter
Balasubramanian Venkataraman
Cell Therapeutics Inc.
Seed IP Law Group PLLC
LandOfFree
Aryl triazines as LPAAT-β inhibitors and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aryl triazines as LPAAT-β inhibitors and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl triazines as LPAAT-β inhibitors and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3807630